Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Liraglutide181 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A15820 | 28694246 | Eur J Endocrinol | MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease. | 2017 | Details |
| A15850 | 28681988 | Diabetes Obes Metab | Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. | 2017 | Details |
| A16216 | 28503750 | Diabetes Obes Metab | Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial. | 2017 | Details |
| A16234 | 28494529 | Clin Mol Hepatol | NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. | 2017 | Details |
| A16533 | 28332301 | J Diabetes | Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. | 2017 | Details |
| A16628 | 28276774 | Expert Rev Clin Pharmacol | Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. | 2017 | Details |
| A17201 | 27916783 | Endocr J | Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. | 2016 | Details |
| A17587 | 27732328 | J Clin Endocrinol Metab | Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study. | 2017 | Details |
| A17622 | 27711029 | Minerva Endocrinol | Adipose tissue, obesity and non-alcoholic fatty liver disease. | 2016 | Details |
| A17704 | 27646933 | Gut | Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. | 2016 | Details |
| A17740 | 27627981 | Diabetologia | Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. | 2016 | Details |
| A18085 | 30695468 | Rinsho Byori | [Progress in the Management of NAFLD/NASH]. | 2016 | Details |
| A18188 | 27301803 | Metabolism | Pharmacological management of nonalcoholic fatty liver disease. | 2016 | Details |
| A18288 | 27239734 | Lab Invest | C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis. | 2016 | Details |
| A18326 | 27208776 | Biochem Biophys Res Commun | GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway. | 2016 | Details |
| A18538 | 27063275 | Clin Liver Dis | Emerging Therapies for Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A18554 | 28702244 | Clin Diabetes Endocrinol | Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. | 2016 | Details |
| A18671 | 27003143 | Dig Dis Sci | Novel Pharmacotherapy Options for NASH. | 2016 | Details |
| A18741 | 26976710 | Endocrinol Nutr | Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. | 2016 | Details |
| A18757 | 26968296 | J Pak Med Assoc | Endocrine and metabolic effects of Glucagon like peptide 1 receptor agonists (GLP1RA). | 2016 | Details |
| A18989 | 26830854 | Endocrinol Nutr | Baseline ALT levels as a marker of glycemic response to treatment with GLP-1 receptor agonists. | 2016 | Details |
| A19186 | 28670148 | Clin Med Insights Ther | Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. | 2016 | Details |
| A19265 | 26666995 | Hepatol Res | Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3-FOXO3a pathway. | 2016 | Details |
| A19297 | 26640549 | Exp Ther Med | Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway. | 2015 | Details |
| A19360 | 26608256 | Lancet | Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. | 2015 | Details |
| A19727 | 26394161 | J Hepatol | Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. | 2015 | Details |
| A20038 | 26195184 | Expert Opin Biol Ther | Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. | 2015 | Details |
| A20113 | 26147696 | Hepatol Res | Glucagon-like peptide-1 preserves non-alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway. | 2015 | Details |
| A20460 | 25947915 | Biol Pharm Bull | The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease. | 2015 | Details |
| A20978 | 25606030 | Case Rep Gastroenterol | A 25-year-old woman with type 2 diabetes and liver disease. | 2014 | Details |
| A21117 | 25531383 | Zhonghua Gan Zang Bing Za Zhi | [Liraglutide protects against nonalcoholic fatty liver disease in ApoE knockout mice with high-fat diet and silenced Acrp30 by increasing AMPK]. | 2014 | Details |
| A21126 | 25526792 | BMJ Open | Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. | 2014 | Details |
| A21723 | 25091053 | Clin Pharmacokinet | Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. | 2014 | Details |
| A22132 | 24796231 | Hepatol Res | Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). | 2014 | Details |
| A22672 | 24373179 | Diabetes Obes Metab | APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. | 2014 | Details |
| A22765 | 24322742 | Hepatobiliary Pancreat Dis Int | Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. | 2013 | Details |
| A22860 | 24273273 | Nan Fang Yi Ke Da Xue Xue Bao | [Effects of glucagon-like peptide-1 on liver oxidative stress, TNF-α and TGF-β1 in rats with non-alcoholic fatty liver disease]. | 2013 | Details |
| A22882 | 24256515 | Clin Endocrinol (Oxf) | Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. | 2013 | Details |
| A23559 | 23676586 | Intern Med | Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus. | 2013 | Details |
| A23842 | 23432843 | Liver Int | GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. | 2013 | Details |
| A24090 | 23236362 | PLoS One | Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. | 2012 | Details |
| A24163 | 23163663 | Aliment Pharmacol Ther | Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. | 2012 | Details |
| A24411 | 22927782 | ScientificWorldJournal | The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. | 2012 | Details |
| A25238 | 22059955 | Health Technol Assess | Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. | 2011 | Details |
| A25321 | 21957486 | PLoS One | GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. | 2011 | Details |
| A29068 | 34626851 | Mol Metab | GLP-1 physiology informs the pharmacotherapy of obesity. | 2021 | Details |
| A29479 | 34016612 | Diabetes Care | Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. | 2021 | Details |
| A33056 | 26774017 | Diabetes Metab | Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association. | 2015 | Details |
| A34187 | 24189085 | BMJ Open | Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. | 2013 | Details |
| A42254 | 35088989 | Minerva Surg | Therapeutic effect of liraglutide on type 2 diabetic patients with nonalcoholic fatty liver disease. | 2022 | Details |
| A42614 | 34015974 | Expert Rev Clin Pharmacol | Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. | 2021 | Details |
| A43171 | 32378399 | J Obes Metab Syndr | Current Long-Term Pharmacotherapies for the Management of Obesity. | 2020 | Details |
| A43467 | 31649796 | Prz Gastroenterol | Liraglutide for non-alcoholic fatty liver disease in children and adolescents: has a new era arrived? | 2019 | Details |
| A43475 | 31613385 | Hepatology | Reply. | 2020 | Details |
| A43478 | 31610029 | Hepatology | Letter to the Editor: Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A43731 | 31006135 | Hepatology | Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes. | 2019 | Details |
| A44116 | 29702499 | Curr Opin Cardiol | New antihyperglycaemic agents and cardiovascular disease: let's be optimistic. | 2018 | Details |
| A44578 | 28124012 | Hepatobiliary Surg Nutr | Liraglutide's use in treatment of non-alcoholic fatty liver: an evaluation of the non-alcoholic steatohepatitis study. | 2016 | Details |
| A44587 | 28089090 | J Diabetes Complications | Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs. | 2016 | Details |
| A44594 | 28071092 | Ann Clin Biochem | Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomized, placebo-controlled phase 2 study. | 2016 | Details |
| A44654 | 27788710 | Zhonghua Gan Zang Bing Za Zhi | [Effect of liraglutide on expression of insulin-like growth factor 2-mRNA binding protein 3 in liver in rats with non-alcoholic fatty liver disease]. | 2016 | Details |
| A44711 | 27633289 | Curr Vasc Pharmacol | Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes? | 2016 | Details |
| A44787 | 27312304 | Lancet | Liraglutide for patients with non-alcoholic steatohepatitis - Authors' reply. | 2016 | Details |
| A44788 | 27312303 | Lancet | Liraglutide for patients with non-alcoholic steatohepatitis. | 2016 | Details |
| A44789 | 27312302 | Lancet | Liraglutide for patients with non-alcoholic steatohepatitis. | 2016 | Details |
| A44824 | 27173023 | Curr Vasc Pharmacol | Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed? | 2016 | Details |
| A44858 | 27053230 | Diabetologia | EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. | 2016 | Details |
| A44959 | 26608257 | Lancet | A LEAN treatment for non-alcoholic steatohepatitis. | 2015 | Details |
| A45312 | 25230688 | Mol Med Rep | Liraglutide reduces lipid accumulation in steatotic L‑02 cells by enhancing autophagy. | 2014 | Details |
| A47896 | 29870275 | Diabetes Technol Ther | The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs. | 2018 | Details |
| A47935 | 28847797 | Circulation | Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. | 2017 | Details |
| A49279 | 35803320 | Metabolism | Recent guidelines for non-alcoholic fatty liver disease (NAFLD): Are they already outdated and in need of supplementation? | 2022 | Details |
| A49813 | 35629915 | Metabolites | Renin-Angiotensin System in Liver Metabolism: Gender Differences and Role of Incretins. | 2022 | Details |
| A49865 | 35614896 | Visc Med | Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review. | 2021 | Details |
| A50153 | 35501557 | Curr Obes Rep | Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50745 | 35280867 | Front Med (Lausanne) | Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. | 2022 | Details |
| A50788 | 35266164 | Aliment Pharmacol Ther | Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. | 2022 | Details |
| A51388 | 30623143 | JACC Basic Transl Sci | The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways. | 2018 | Details |
| A51565 | 35081898 | Endocr Metab Immune Disord Drug Targets | Therapeutic effects and mechanism of liraglutide on rats with type 2 diabetes and metabolic-associated fatty liver disease. | 2022 | Details |
| A51686 | 34920733 | Cardiovasc Diabetol | Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. | 2021 | Details |
| A52109 | 31103416 | Biochem Pharmacol | Effects of Liraglutide and Fenretinide treatments on the diabetic phenotype of neuronal human BACE1 knock-in mice. | 2019 | Details |